Cas:74317-53-6 2-amino-3′,6′-bis(diethylamino)spiro[isoindole-3,9′-xanthene]-1-one manufacturer & supplier

We serve Chemical Name:2-amino-3′,6′-bis(diethylamino)spiro[isoindole-3,9′-xanthene]-1-one CAS:74317-53-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-amino-3',6'-bis(diethylamino)spiro[isoindole-3,9'-xanthene]-1-one

Chemical Name:2-amino-3′,6′-bis(diethylamino)spiro[isoindole-3,9′-xanthene]-1-one
CAS.NO:74317-53-6
Synonyms:RhB hydrazide;N-(rhodamine-B)hydrazide;2-amino-3′,6′-bis(diethylamino)spiro[isoindoline-1,9′-xanthen]-3-one;2-amino-12,15-bis(diethylamino)spiro[isoindoline-3,9′-xanthene]-1-one;hydrazine rhodamine;N-(rhodamine-B) lactam-hydrazine;Rhodamine B hydrazide
Molecular Formula:C28H33ClN4O2
Molecular Weight:493.04000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:74.51000
Exact Mass:492.22900
LogP:2.56150

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like RhB hydrazide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Rhodamine B hydrazide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,RhB hydrazide Use and application,2-amino-12,15-bis(diethylamino)spiro[isoindoline-3,9′-xanthene]-1-one technical grade,usp/ep/jp grade.


Related News: The vaccine has been through the ringer over safety worries before. In April, U.S. authorities halted its use and later tagged it with a warning over reports of rare blood clots occurring alongside bleeding in some recipients. (6R)-3-methyl-2-methylsulfanyl-8-oxo-7t-(2-phenyl-acetylamino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2c-carboxylic acid manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. 1-(4-nitrophenethyl)-4-phenyl-1,2,3,6-tetrahydropyridine suppliers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. (1,1-dimethylethyl)dimethylsilyl 1-(2-methoxyethoxy)-pentyl peroxide vendor & factory.